RAYMOND JAMES & ASSOCIATES - HAEMONETICS CORP ownership

HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 268 filers reported holding HAEMONETICS CORP in Q3 2020. The put-call ratio across all filers is 0.64 and the average weighting 0.1%.

Quarter-by-quarter ownership
RAYMOND JAMES & ASSOCIATES ownership history of HAEMONETICS CORP
ValueSharesWeighting
Q3 2023$2,938,314
+17.5%
32,801
+11.6%
0.00%0.0%
Q2 2023$2,501,413
-37.2%
29,380
-39.0%
0.00%
-33.3%
Q1 2023$3,982,344
+209.1%
48,125
+193.8%
0.00%
+200.0%
Q4 2022$1,288,287
+43.1%
16,380
+34.8%
0.00%0.0%
Q3 2022$900,000
-52.8%
12,154
-58.5%
0.00%
-50.0%
Q2 2022$1,907,000
-55.9%
29,258
-57.3%
0.00%
-50.0%
Q1 2022$4,327,000
+49.3%
68,448
+25.2%
0.00%
+100.0%
Q4 2021$2,899,000
+322.6%
54,657
+430.9%
0.00%
+100.0%
Q2 2021$686,000
-68.4%
10,295
-47.3%
0.00%
-50.0%
Q1 2021$2,169,000
-6.2%
19,535
+0.3%
0.00%
-33.3%
Q4 2020$2,313,000
+43.8%
19,481
+5.7%
0.00%
+50.0%
Q3 2020$1,609,000
+386.1%
18,439
+398.2%
0.00%
Q2 2020$331,000
-67.6%
3,701
-63.9%
0.00%
-100.0%
Q1 2020$1,021,000
-76.9%
10,240
-73.4%
0.00%
-66.7%
Q4 2019$4,419,000
-17.2%
38,461
-9.1%
0.01%
-14.3%
Q3 2019$5,336,000
+410.1%
42,299
+386.9%
0.01%
+250.0%
Q2 2019$1,046,000
+18.2%
8,688
-14.1%
0.00%
+100.0%
Q1 2019$885,000
-17.4%
10,115
-5.6%
0.00%
-50.0%
Q4 2018$1,072,000
+53.8%
10,716
+76.1%
0.00%
+100.0%
Q3 2018$697,000
-0.4%
6,084
-22.0%
0.00%0.0%
Q2 2018$700,000
+176.7%
7,805
+125.6%
0.00%
Q1 2018$253,0003,4600.00%
Other shareholders
HAEMONETICS CORP shareholders Q3 2020
NameSharesValueWeighting ↓
Millrace Asset Group, Inc. 19,264$1,7262.13%
Parkman Healthcare Partners LLC 88,962$7,969,2161.46%
HEARTLAND ADVISORS INC 256,414$24,435,2741.37%
Riverwater Partners LLC 15,553$1,393,2381.27%
KINGDON CAPITAL MANAGEMENT, L.L.C. 111,100$9,952,3381.15%
Lisanti Capital Growth, LLC 78,425$7,025,3121.11%
Aristotle Capital Boston, LLC 311,666$27,919,0540.90%
ROYCE & ASSOCIATES LP 947,550$84,881,5290.86%
CHASE INVESTMENT COUNSEL CORP 18,770$1,6810.84%
Virtus Investment Advisers, Inc. 13,662$1,223,8420.83%
View complete list of HAEMONETICS CORP shareholders